Business
New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate // Motley Fool Australia
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
On Wednesday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) presented new data from a final efficacy analysis on their BNT162b2 vaccine candidate, and the news was very good.
In a joint press release, the 2 partners said the vaccine met all of its primary efficacy endpoints. Better still, it had an efficacy rate of 95% in participants both with and without prior coronavirus infection (mild or severe). Also, the vaccine’s efficacy was consistent across key demographics such as age, gender, and ethnicity. No serious safety concerns were reported.
That rate, meanwhile, is higher than the 90%-plus demonstrated in the…
-
General20 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
Noosa News23 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
General22 hours agoVulnerable youth non-for-profit Allambi Care agrees to end ‘unacceptable’ housing scheme
-
Noosa News23 hours agoRosemarie Campbell’s post-surgery deterioration score miscalculated at The Wesley Hospital, inquest into her death hears